AngioDynamics has completed enrolling patient for its NanoKnife System trial (ONC-205) to treat early-stage hepatocellular carcinoma (HCC).
The multi-center, prospective, European study is designed to assess the safety and efficacy of the NanoKnife System.
The patients, who were having one to three tumors of a size no greater than 3 cm, were selected for the study.
The primary endpoint is tumor response assessment at 30-days post treatment with imaging.
With subjects followed to end-of-life to determine overall survival as a secondary endpoint.
AngioDynamics president and CEO Joseph DeVivo said the clinical results will be of particular interest as the subjects have not been treated with other modalities, meaning any response obtained is directly attributable to the NanoKnife System.